ClinConnect ClinConnect Logo
Search / Trial NCT02690935

Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen

Launched by LABO'LIFE · Feb 23, 2016

Trial Information

Current as of May 28, 2025

Completed

Keywords

Grass Pollen Homeopathy Placebo Quality Of Life

ClinConnect Summary

The primary objective of this study is to demonstrate the superiority of 2L®ALERG over placebo in terms of efficacy on the symptoms of allergic rhinitis and allergic rhinoconjunctivitis in patients with seasonal allergy to grass pollen, corrected according to rescue medication intake. The secondary objectives are to compare the allergy symptoms, the rescue medication intake, the quality of life and the safety in patients treated with 2L®ALERG or with a placebo.

This is a multicentre, randomized, double-blind, two-parallel group, interventional placebo-controlled study with a notified homeo...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥18 years, male and female
  • Woman of childbearing age using effective contraceptive means
  • Patient having the faculties to understand and respect the constraints of the study
  • Symptomatic since at least two seasons and confirmed by positive skin test and/or the presence of IgE for grasses (prick test defined as positive if higher than or equal to half the negative control; IgE positive if at least class 3 (≥ 3.5 kU / L); these tests must have been performed at the latest at the first screening visit
  • Signature of the Informed Consent Form
  • Exclusion Criteria:
  • Pregnant woman or woman wishing to become pregnant
  • Breastfeeding woman
  • Patient with an acute exacerbation of allergic rhinitis
  • Patient with uncontrolled asthma
  • Immunotherapy received within the last two years
  • Patient with a known lactose intolerance
  • Patient who participated in a clinical study in the previous three months
  • Patient who is not sufficiently motivated to engage on a follow-up period of 6 months or more, unable to complete the patient diary, or likely to travel or to move before the end of the study,
  • Patient taking nasal or bronchial inhaled corticosteroids on a long term basis (intermittent consumption during the season is permitted provided it is mentioned in the patient's records)

About Labo'life

labo'life is a forward-thinking clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on improving patient outcomes, labo'life specializes in conducting robust clinical trials across various therapeutic areas, leveraging cutting-edge technologies and methodologies. Committed to ethical practices and regulatory compliance, the organization collaborates closely with healthcare professionals, regulatory authorities, and patients to ensure the highest standards of safety and efficacy in its studies. By fostering a patient-centered approach, labo'life aims to contribute significantly to the advancement of medical knowledge and the development of novel therapies.

Locations

Linkebeek, , Belgium

Patients applied

0 patients applied

Trial Officials

Stéphane Heijmans, MD

Principal Investigator

ResearchLink

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials